| General Information | |
|---|---|
| ZINC ID | ZINC000084632074 |
| Molecular Weight (Da) | 437 |
| SMILES | O=C(O)c1cccc(NC(=O)c2cc3c(n(CC4CCCCC4)c2=O)CCCCCC3)c1 |
| Molecular Formula | C26N2O4 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 123.008 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 32 |
| LogP | 5.881 |
| Activity (Ki) in nM | 616.595 |
| Polar Surface Area (PSA) | 88.4 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | - |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | - |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | - |
| Androgen receptor binding | + |
| Plasma protein binding | 0.98148834 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 12 |
| Fraction csp3 | 0.5 |
| Ilogp | 2.7 |
| Xlogp3 | 5.17 |
| Wlogp | 4.85 |
| Mlogp | 3.97 |
| Silicos-it log p | 4.5 |
| Consensus log p | 4.24 |
| Esol log s | -5.69 |
| Esol solubility (mg/ml) | 0.000901 |
| Esol solubility (mol/l) | 0.00000206 |
| Esol class | Moderately |
| Ali log s | -6.77 |
| Ali solubility (mg/ml) | 0.0000737 |
| Ali solubility (mol/l) | 0.00000016 |
| Ali class | Poorly sol |
| Silicos-it logsw | -6.39 |
| Silicos-it solubility (mg/ml) | 0.000176 |
| Silicos-it solubility (mol/l) | 0.0000004 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.29 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.56 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.62 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -3.445 |
| Logd | 3.78 |
| Logp | 6.334 |
| F (20%) | 0.917 |
| F (30%) | 0.998 |
| Mdck | - |
| Ppb | 98.66% |
| Vdss | 0.342 |
| Fu | 0.55% |
| Cyp1a2-inh | 0.273 |
| Cyp1a2-sub | 0.165 |
| Cyp2c19-inh | 0.473 |
| Cyp2c19-sub | 0.06 |
| Cl | 1.533 |
| T12 | 0.205 |
| H-ht | 0.913 |
| Dili | 0.927 |
| Roa | 0.56 |
| Fdamdd | 0.831 |
| Skinsen | 0.334 |
| Ec | 0.003 |
| Ei | 0.023 |
| Respiratory | 0.626 |
| Bcf | 0.787 |
| Igc50 | 4.916 |
| Lc50 | 3.762 |
| Lc50dm | 4.22 |
| Nr-ar | 0.296 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.627 |
| Nr-aromatase | 0.703 |
| Nr-er | 0.514 |
| Nr-er-lbd | 0.012 |
| Nr-ppar-gamma | 0.977 |
| Sr-are | 0.317 |
| Sr-atad5 | 0.009 |
| Sr-hse | 0.712 |
| Sr-mmp | 0.913 |
| Sr-p53 | 0.847 |
| Vol | 460.089 |
| Dense | 0.948 |
| Flex | 0.214 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 4 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.687 |
| Synth | 2.39 |
| Fsp3 | 0.5 |
| Mce-18 | 57.538 |
| Natural product-likeness | -1.033 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |